8-K current report · filed Nov 4, 2026

Nuvectis Pharma, Inc. (NVCT) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1NVCT overview

Short answer

Nuvectis Pharma, Inc. (NVCT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.

Nuvectis Pharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the substantive results and management update for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Third-quarter 2026 results reflect major pipeline expansion, with China approval for ciprocopan and $140.7M cash extending runway into 2H 2029
  • Ciprocopan’s U.S. path remains the key catalyst, with FDA discussions underway and an update expected before year-end
  • NXP200 showed 40.0% ORR in high-grade glioma and 42.9% in low-grade glioma, including complete responses
  • Net loss widened to $30.1M from $7.5M, primarily reflecting $20.0M upfront licensing and $1.8M NXP900 milestone payments
  • Funding included $115.0M follow-on proceeds and $39.5M ATM proceeds, while shares outstanding rose to 35,031,982 from 25,676,798

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nuvectis Pharma, Inc. 8-K filings

Get the next NVCT 8-K as it lands

Follow NVCT for push alerts, or ask the research agent what this filing means.